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Pulmonary Metabolism of Foreign
Compounds: Its Role in Metabolic
Activation
by Gerald M. Cohen*
Thelunghasthepotentialofmetabolizingmanyforeignchemicalstoavastarrayofmetabolites with
differentpharmacological andtoxicological properties. Becausemanychemicalsrequiremetabolicac-
tivation inorder to exerttheirtoxicity, the cellular distribution ofthe drug-metabolizing enzymes in
a heterogeneous tissue, such as the lung, and the balance of metabolic activation and deactivation
pathwaysinanyparticularcellarekeyfactorsindeterminingthecellularspecificityofmanypulmonary
toxins. Enviroxnmental factors such as air pollution, cigarette smoking, and diet markedly affect the
pulmonary metabolism of some chemicals and, thereby, possibly affect their toxicity.
Introduction
The lungisthe majorportal ofentry into the body of
all inhaled compounds such as those contained in pol-
luted cityair, tobaccosmoke, andmedicinalandhouse-
hold aerosols. The verylarge surface areaofthe alveoli
(about 70 m2) besides beingideally suited forthe func-
tion of gas exchange, also facilitates the penetration
into the body of these potentially toxic agents. As the
entire cardiac output passes through the lungs, all
chemicals present in the circulation must also traverse
thelungs. Notsurprisingly, manyoftheforeignchemicals
andbiological agents to whichthe airways are exposed
have been implicated in a wide variety of diseases of
the respiratorytract, forexample, lungcancer(tobacco
smoke, benzo(a)pyrene, nitrosamines, polonium-210,
chromates, nickel and arsenic); chronic bronchitis and
emphysema (cigarette smoking and air pollution); dif-
fusepulmonaryfibrosis(busulfan, bleomycin, nitrofur-
antoin, methysergide, paraquat, methylphenylethylhy-
dantoin, anddiphenylhydantoin); andphospholipidoses
(chlorphentermine).
The lung is exposed to a wide variety of exogenous
chemnicals that may exert profound pharmacological,
therapeutic, or toxicological actions. These chemicals
may be metabolized bythe lung, possibly increasing or
decreasingtheirtoxicityorpharmacological action(1-4).
Theenzymesresponsibleforthepulmonarymetabolism
of these foreign chemicals (xenobiotics) include both
mixed-function oxidases and enzymes catalyzing con-
jugation reactions and are the subject of this review.
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Pulmonary Drug-Metabolizing
Enzymes
While the liverhas been recognized as the major site
of drug or xenobiotic (foreign compound) metabolism,
recently much attention has also been paid to the
metabolism ofxenobioticsbyextrahepatictissues, inpar-
ticular, at portals of entry into the body (i.e., the lung,
intestine, andskin), whichismarkedlyinfluencedbythe
environment, dietarystatus, andpriorexposuretoother
chemicals (5). Owing to a deficiency of good data, it is
difficult to assess the contribution of pulmonary
metabolism to the overall metabolism of a compound.
In most cases, in vitro enzymic activities of liver are
significantly higher than those of lung, but these dif-
ferences may be offset in vivo by other factors such as
bloodflowanddistribution. Thus, withcompoundssuch
as certain amines that are concentrated in lung tissue
(2,6), the contribution of the lung to the overall
metabolism of the compound may be far greater than
can be determined from in vitro enzymic activities.
The metabolic transformations, which most xeno-
bioticsundergo inthe body, are numerous and diverse,
but they may be conveniently classified into two main
phases (7). In phase I, compounds may undergo either
oxidation, reduction, or hydrolysis reactions generally
resulting in the addition or exposure of functional
groups, such as -OH orCOOH, which may then undergo
phase II or synthetic (conjugation) reactions. The net
result of such phase I and II metabolism is often the
productionofmorepolar, lesslipid-soluble, more readi-G. M. COHEN
ly excretable, and less biologically active compounds.
This overall scheme is illustrated below:
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These differences may, in part, be due to the presence
ofdifferentisozymesofcytochromeP-450; inrabbitlung
atleasttwohavebeendescribedwithmarkedlydifferent
substratespecificitiesandbiologicalactivities(8). Thus,
the intracellular distribution of different isozymes of
cytochromeP-450mayplayakeyroleindeterminingthe
cellular specificity of some toxins to the lung. Various
reductases and esterases have also been found in dif-
ferentsubcellularfractionsoflung (Dible 1), ofteninthe
cytosol.
Many chemicals that already possess functional groups
may undergo phase II reactions directly.
Phase I Reactions
ManyphaseIreactions, inparticularoxidations, are
carried out in the endoplasmic reticulum (microsomes)
ofthecell. Thesereactionsarecatalyzedbyamicrosomal
mixed-functionoxidasesystem, whichrequiresNADPH
andmolecularoxygen. Theterminaloxidase ofthissys-
temiscytochrome P-450(socalledbecauseoftheabsorp-
tionpeak at450 nm when the reduced microsomes are
bubbled with carbon monoxide). This enzyme system
appears to be unique in having such a broad substrate
specificity. Its activity may also be markedly enhanced
byprioradministrationofotherxenobiotics. Whilemuch
of what is known about the xenobiotic metabolizing
enzymesystemscomesfromstudiesontheliver, compar-
ableworkonthelungemphasizesthesimilaritiesrather
than the diversities of this enzyme system in different
tissues. However, with some compounds important
qualitative andquantitativedifferencesarefoundinthe
metabolitesformedandtheinducibilityoftheenzymes.
Phase 11 Reactions
PhaseIIsynthetic orconjugationreactionsgeneral-
lyinvolvetheadditionofsmallendogenouscompounds
tothexenobiotic orits metabolite(s). Suchendogenous
compoundsincludeuridinediphosphateglucuronic acid
(UDPGA), 3'-phosphoadenosine 5'-phosphosulphate
(PAPS), S-adenosylmethionine, acetyl-CoAandglutath-
ione inglucuronidation, sulfation, methylation, acetyla-
tion, andglutathioneconjugation reactions, respectively
(7). All these conjugation reactions have been
demonstrated in pulmonary tissues (Thble 2).
Since much of the in vitro data have been obtained
using varioussubcellularfractions, itshouldbeempha-
sizedthatcautionmustbeexercisedinextrapolatingthis
data to possible in vivo significance, since the loss
of structural integrity on homogenization or damage
causedbyslicingthelungmayresultinenzymeactivities
in vitro that are not observed either in vivo or in the
isolated perfused lung. This is well illustrated in some
examples.
Histamine is metabolized by slices or homogenates
of human, cat, guinea pig, and rat lung, but not by
isolatedperfusedlungsofthedog orrat(27). Ithasbeen
Table 1. Phase I reactions catalyzed by pulmonary tissues.
Reaction
Oxidation
Side-chain oxidation,
Pentobarbitone >
Aromatic hydroxylation,
Benzo(a)pyrene
N-Dealkylation,
Nortriptyline
N-Hydroxylation,
N-Methylaniline
O-Dealkylation,
Ethoxyresorufin
Epoxidation,
Aldrin
Reduction
Nitroreductase,
Nitrazepam
Ketone reductase,
Acetophenone
N-Oxide reductase,
Imipramine N-oxide-
Hydrolysis
Acetylcholinesterase,
Acetylcholine
5-Ethyl-5-(3' -hydroxyl-l' -methylbutyl) barbituric acid
3-Hydroxybenzo(a)pyrene
Desmethylnortriptyline
Phenylhydroxylamine +aniline
Resorufin
Dieldrin
7-Aminonitrazepam
1-Phenylethanol
Imipramine
Choline + acetate
oxidation
reduction
hydrolysis
Reference
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
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Table 2. Phase II reactions catalyzed by pulmonary tissues.
Reference Reaction
Glucuronide conjugation,
4-Methylumbelliferone > 4-Methylumbelliferone glucuronide (19)
Sulfate conjugation,
3-Hydroxybenzo(a)pyrene > Benzo(a)pyren-3-yl-hydrogen sulfate (20)
Methyltransferases
N-Methyltransferase,
5-Hydroxytryptamine > N-Methyl 5-hydroxytryptamine (21)
O-Methyltransferase,
Phenol > Anisole (22)
S-Methyltransferase,
Mercaptoethanol > S-Methylmercaptoethanol (23)
Catechol O-methyltransferase,
Isoprenaline > 3-O-Methylisoprenaline (24)
Acetylation,
Sulfanilamide > N4-Acetylsulfanilamide (25)
Glutathione conjugation,
Benz(a)anthracene 5,6-oxide S-(5,6-dihydro-6-hydroxybenz(a)anthracen-5-yl)-
glutathione (26)
suggested that in the perfused lung apermeability bar-
rierpreventsthehistaminefromreachingitsinactivating
enzyme. Similar results have also been obtained show-
ingmetabolismofangiotensinHinlunghomogenatesbut
notinisolatedperfused lungs(27). Whilethepreviously
mentioned examplesapplytorelativelypolarendogen-
ouscompoundswhere onemayexpectpermeabilitybar-
riers, similar problems have also been observed with
some lipophilic compounds.
Inacomparative studyofthemetabolism ofxenobio-
tics by isolated perfused rabbit lung and lung micro-
somes, nodetectable metabolism ofeitherchlorcyclizine
and imipramine was observed using isolated perfused
lung, whereassignificantmetabolismwasobservedusing
lungmicrosomes(9). Inthesamestudyothersubstrates
suchasmethadone, pentobarbitone, andparathionwere
metabolized to qualitatively similar metabolites by
isolated perfused lungs or microsomes. The absence of
detectablemetabolismofchlorcyclizine andimipramine
in the isolated perfused lungs may be very significant.
Asbothofthesecompoundsareconcentrated inlung
tissue (6), the results suggest that their sites of uptake
and storage are different from the pulmonary metabo-
lizing enzymes, and also that these compounds cannot
apparentlygainaccesstotheenzymes. Someaminesthat
arestoredinthelungs aremetabolized, suchasnortrip-
tyline (11). This raises the possibility that there may be
discrete storage sites in the lung for these compounds.
Fromthe previous discussion, the problems inherent
inextrapolatinginvitrodatafromsubcellularfractions
to in vivo significance are only too apparent. For this
reason, in vitro data obtained using different prepara-
tionsoflungaremorereliablethandataobtainedusing a
single preparation such as a homogenate, particularly
when one of these methods involves using an isolated
perfused lung preparation. As seen in Thbles 1 and 2,
the lung has the inherent capability of metabolizing
chemicals by a large number ofdiverse chemical path-
ways, and the extent to which this metabolic potential
is realized in vivo is very complex.
Pulmonary Metabolism of Chemicals
in Relation to Their Toxicity
Because of the pioneering work of the Millers and
many other groups, it is now recognized that many
chemicals require metabolic activation before exerting
their toxicity (1,28,29). This activation may take place
in the lung or in another tissue such as liver. The pos-
sible contribution ofextrapulmonary metabolic activa-
tionofchemicalstometabolitesthataretoxictothelung
will depend, in part, on the relative stability of such
metabolites and the inherent susceptibility to toxicity
of the lung compared to other tissues. Alternatively a
stable, proximate, toxicmetabolitemaybeformedinan
extrapulmonary site, transported to the lung, and then
metabolized totheultimatetoxicform. Finally, thelung
maybe responsible forthe formation ofthe toxic meta-
bolitefromtheparentchemical(Fig. 1). Thesepotential
mechanisms have been reviewed elsewhere (1,30,31).
Inconsideringthegeneration ofreactive metabolites
inthelung, itisessentialtoconsiderboththeactivating
and deactivating enzymes. The balance of the activity
oftheseenzymesandtheirrespectivecofactorsandtheir
cellulardistributionultimatelydetermineshowmuchof
areactivemetabolite(s)maybepresentinthelungand,
therefore, availableforinteractionwithcriticalcellular
targets leading to toxicity (1,30,32). Some of these
enzymesandtheircofactors areshowninTable3. Obvi-
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FIGURE 1. Toxicity mediated by reactive metabolites formed inthe lungeitherfrom the parent chemical orfrom proximate toxic metabolite.
If the toxic metabolite is chemically very reactive, it may have to be generated in situ in the lung in order to exert toxicity. Depending
onthe metabolic capability ofthetissue, the metabolic activationby the parentchemical maybe completely carried out inthe lung. Alter-
natively, partofthemetabolic activation maybecarried outinothertissues, such astheliver, butthe ultimate toxic metabolites areformed
in situ in the lung.
Ihble 3. Balance of activating and deactivating enzymes
and their cofactors.
Cytochrome P-450 NADH-cytochrome b5 reductase
Prostaglandin synthetase Xanthine oxidase
Flavin-containing Glutathione
monooxygenase
Glutathione peroxidase
Glutathione S-transferase
NADPH-cytochrome P-450 UDP-glucuronosyltransferase
reductase
Catalase Vitamin E
Superoxide dismutase Ascorbic acid
NAD(P)H
ously, therelativeimportanceofthese willdifferfordif-
ferent chemicals. It is also important to note that many
ofthese enzymeactivities maybealteredbyvarious en-
vironmental agents, thus potentially affecting the
pulmonary toxicity of some chemicals.
Pulmonary Cell Types Responsible
for Metabolism of Xenobiotics
Thelungisaverycomplexorgancomposedofatleast
40different celltypes(33). Thebalanceofactivatingand
deactivating enzymesandtheircofactors in aparticular
celltypeinthelung may, inpart, determine thecellular
specificity ofthetoxicchemical(34). Earlyhistochemical
studies demonstrated mixed-function oxidase activity
(benzo(a)pyrene3-monooxygenase) inthealveolar walls,
butnotinthetracheal orbronchial mucosa(5). Byusing
a different histochemical technique, aniline 4-hydrox-
ylase wasdemonstratedinbothalveolartissueandbron-
chial epithelium, and the enzymic activity appeared
greatest in the latter (35). One group of cells easily ob-
tained from lung are alveolar macrophages. Rabbit
alveolar macrophages possessed high levels of acetyl
transferase, buttheylackeddetectableactivityofbenzo-
(a)pyrene3-monooxygenase, eveninanimalspretreated
with 3-methylcholanthrene (36). However, important
species differences are also observed in pulmonary
metabolism, e.g., human alveolar macrophages have
been shown to metabolize benzo(a)pyrene to reactive
metabolites (3?).
By using autoradiographic and immunohistochem-
ical methods, it was shown that much ofthe total lung
content of cytochrome P-450, the mixed-function oxi-
dase responsible for the activation of many chemicals
toreactivemetabolites, waslocalized inthe nonciliated
bronchiolarepithelial(Clara)cells(38,39). Thisprovided
a metabolic basis for the susceptibility of this cell type
to many pulmonary toxins including 4-ipomeanol, 3-
methylfuran, and naphthalene (lible 4). The nature of
the isozyme of cytochrome P-450 (8) present in a par-
ticular cell type may also be of importance. However,
otherfactorsmustalsobeofimportanceindetermining
the marked susceptibility of the Clara cells to damage
because some chemicals in lble 4, e.g., methylcyclo-
pentadienyl manganesetricarbonyl(40), do not appear
torequire metabolicactivationbyClaracellsinorderto
exerttheirtoxicity. Thespecificexampleof4-ipomeanol
is considered in more detail later.
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¶lkble 4. Chemicals causing damage to Clara cells.
Chemical Occurrence
4-Ipomeanol Moldy sweet potatoes
3-Methylfuran Atmospheric pollutant
Naphthalene Industrial chemical, moth balls
2-Methylnaphthalene Food, cigarette smoke
1-Nitronaphthalene Diesel exhaust
3-Methylindole Ruminal fermentation product
oftryptophan, cigarette smoke
1,1-Dichloroethylene Copolymer in plastics industry,
food and water
Bromobenzene Industrial chemical
CC14 Organic solvent
O,O,S-Trimethyl Impurity in organophosphorous
phosphorothioate insecticides
03 and NO2 Environmental pollutants
Organometallic carbonyls Gasoline
Methylcyclopentadienyl
Manganese tricarbonyl
Morerecently, workfromDevereuxandFouts(41)and
a number of groups has concentrated on isolating dif-
ferentlung celltypes-inparticular, Claracellsandalveo-
larTypeIIcells-anddeterminingtheirmetabolic capa-
bilities. Despitethe limitations ofsuchmethods such as
the loss of enzyme activities or cofactors during isola-
tion, much valuable information maybe obtained from
isolated cells. These studies have demonstrated the
presence of a number of drug-metabolizing enzymes
including mixed-function oxidase, UDP-glucuron-
osyltransferase, epoxide hydrolase, and glutathione S-
transferase inbothisolatedlype II cellsand Claracells.
Ingeneral, higherlevelsofmixed-functionoxidaseactiv-
ityarepresentinClaracells, comparedtolevelsinlype HI
cells(41). However, differences areobserveddependent
on the substrate chosen for study, implying a possible
differential distribution of different isozymes of
cytochrome P-450 in different cell types in agreement
with immunohistochemical studies (39).
While mostattentionhasbeendevoted toTEype IIand
Claracells, mixed-functionoxidaseactivityisalsofound
in other cell types in the respiratory tract including
trachealandbronchial epithelialcells, ciliatedcells, and
pulmonaryalveolarmacrophagesfrom somespecies. The
cellularheterogeneity ofthelungpresents enormnousdif-
ficulties tothe isolation ofallbut afew ofthe many cell
typesinsufficientyieldandviabilityrequired formeta-
bolic studies. Thus, the most recent advances on the
distribution of the drug-metabolizing enzymes in the
respiratory tract have been provided by immunohisto-
chemical and immunofluoresence methods in conjunc-
tion with fluorescence histochemical methods (42).
These resultsdemonstratethatthere are numeroussites
within the respiratory tract where xenobiotics may be
metabolized and that the enzymes are not distributed
uniformly. In untreated rat lungs benzo(a)pyrene was
hydroxylated by bronchial, Clara, and ciliated bron-
chiolar epithelial cells, as well as TEype II pneumocytes
and other cells in the alveolar wall. These studies also
showed that the bronchus, bronchiole, and alveolar
wallscontained antigensrelated toNADPH-cytochrome
P-450 reductase; cytochromes P-450, phenobarbitone
(PB-B), and pregnanalone-16a-carbonitrile (PCN-E);
epoxide hydrolase; andglutathioneS-transferasesB, C,
and E; but only very low levels of cytochrome P-450,
f3-naphthoflavone (BNF-B) (42). On induction with
Aroclor 1254, benzo(a)pyrene hydroxylase, but not
cytochromes P-450, BNF-B, or 3-methylcholanthrene
(MC-B), were induced throughout the bronchial and
bronchiolar epithelia, suggesting that other immuno-
chemically unrelated cytochrome P-450 isozymes were
induced (42).
Veryrecently, anultrastructuralimmunocytochemical
characterization ofcytochrome P-450inrabbitlunghas
further increased our knowledge of its distribution in
the respiratory tract (43). Antisera against the major
pulmonary microsomal cytochrome P-450 isozymes
2 and 5andNADPH-cytochrome P-450reductasebound
specifically to regions rich in agranular endoplasmic
reticulum in the cytoplasm of Clara cells. The plasma
membranesofbronchiolarClaracells, thetipsofmicro-
villaeofciliatedcells, secretorygranulesofgobletcells,
andthecellmembraneandpinocytoticvesiclesofendo-
thelial cells were intensely labeled with antisera from
isozymes 2 and 5, but not to the reductase. Differences
inthedistributionofP-450isozymeswerealsonotedwith
the Golgi membranes of ciliated cells being labeled in-
tensely by antisera to isozyme 5 only (43). The physio-
logical and toxicological significance of these findings
isnotyetclear, butfurther studiesofthisnatureshould
prove to be of great value.
Specific Examples
There are many examples of chemicals where
pulmonary metabolicactivationhasbeenimplicatedin
theirpulmonarytoxicity. Someofthesearesummarized
in lhble 5, but rather than give a detailed review of all
these chemicals, I have chosen to illustrate the gen eral
principlesinvolvedwithtwowell-documentedexamples,
i.e., benzo(a)pyrene and 4-ipomeanol.
Benzo(a)pyrene
Reviews of the metabolism of carcinogens, in par-
ticular, polycyclic aromatichydrocarbonsbyrespiratory
tissueshavebeenpublished(44,45). Polycyclicaromatic
hydrocarbons suchasbenzo(a)pyrene areubiquitousen-
vironmentalcarcinogens. Hundredsoftonsofbenzo(a)-
pyreneareemittedannuallyintotheatmosphere. Much
oftheseemissionsarisefromheatandpowergeneration,
the burning ofrubbish, and car exhausts. As benzo(a)-
pyreneisalsofoundincigarettesmoke, muchefforthas
beendevoted toelucidatingthepossible role ofthisen-
vironmental carcinogen in the etiology of lung cancer.
Thepulmonary metabolismofbenzo(a)pyrene iscon-
sideredindetailbecauseitillustratesimportantgeneral
principlessuchasa)theversatilityofthepulmonaryen-
zymes as reflected by the large number of metabolites
obtainedfromtheparentcompound; b)theactivitiesof
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Tble 5. Enzymes involved in the metabolic activation of various pulmonary toxins.
Compound Source Toxicity Enzymes involved
Benzo(a)pyrene Cigarette smoke Lung cancer P-448, epoxide hydrolase, PES
4-Ipomeanol Moldy sweet potatoes Clara cell necrosis P-450
3-Methylfuran Environmental pollutant Clara cell necrosis P-450
Parathion Insecticide Respiratory edema and failure P-450, amine oxidase
a-Naphthylthiourea Rodenticide Edema P-450, amine oxidase
Carbon tetrachloride Organic solvent Clara and Type II cell damage P-450
Nitrofurantoin Antibacterial Fibrosis P-450 reductase, xanthine oxidase
Paraquat Herbicide Type I and II cell damage P-450 reductase
Naphthalene Moth balls Clara cell necrosis P-450, glutathione S-transferase
Butylated hydroxytoluene Food additive Type I cell damage (mice) P-450
3-Methylindole Bacterial metabolite of Edema, Clara cell necrosis P-450
trypotophan
p-Xylene Solvent Decrease in pulmonary P-450, deficiency of alcohol and
mixed-function oxidases aldehyde dehydrogenase
4-(N)Methyl-N-nitrosoamino)- Tbbacco Carcinogen P-450
1-(3-pyridyl)-1-butanone
theseenzymesmaybedramaticallyalteredbyexposure
to a wide variety of environmental chemicals; c) the
possibleimportanceofstudyingthemetabolismofacom-
poundinitstargettissue; andd)themetabolism ofben-
zo(a)pyrene is representative of other environmental
polycyclichydrocarbonssuchasdibenz(a,h)anthracene,
dibenzo(a,i)pyrene, and benzo(c)phenanthrene.
It is well known, primarily due to the work of the
Millers, thatmanychemicalcarcinogenshave tobemeta-
bolically activatedbeforeexertingtheircarcinogenic ac-
tions(28). Although active metabolites may be formed
in the liver and then transported to the lung, it is more
likely that highly reactive metabolites are formed in
susceptible tissues. Thus, much attention has recently
beenfocusedbothonthepulmonarymetabolism ofben-
zo(a)pyrene andthemanyenvironmentalfactorsthatby
affectingthis metabolism may alteritscarcinogenicity.
Polycyclic aromatic hydrocarbons aremetabolized by
the microsomal mixed-function oxidase system
(E.C.1.14.14.2, aryl hydrocarbon hydroxylase [AHH],
benzo(a)pyrene3-monooxygenase)foundinmanytissues
of different species including the lungs of man, rat,
hamster, mouse, guineapig, andrabbit. Manyimportant
environmental agents such as cigarette and marijuana
smoke and ozone, as well as compounds such as
3-methylcholanthrene alterpulmonarybenzo(a)pyrene
3-monooxygenase activity. Rat pulmonary benzo(a)-
pyrene3-monooxygenase activity wasdecreasedby 27%
after 1 hrofexposure tocigarette smoke, butincreased
after4hrofexposure(46). Thisincrease wasapparent-
ly due to enzyme induction, since it was abolished by
prior administration of either actinomycin D or puro-
mycin. The time course of induction was studied after
exposure tocigarette smoke for4hr. Someinductionof
enzymic activity was observed immediately after ex-
posure; this increased toamaximumof28-fold at24hr
andremainedhighuntilday6whenitreturnedtoalmost
control level. These studies suggested the presence of
potentinducersofratlungbenzo(a)pyrene 3-monooxy-
genaseactivityincigarettesmokethatwereretainedin
thelungaftersmoking. Ithasalsobeenshownthatben-
zo(a)pyrene3-monooxygenaseactivity presentinhuman
pulmonary alveolar macrophages is significantly in-
duced by an inhalation of cigarette smoke (47).
Otherfactorssuchasdietalsoaffectpulmonarybenzo-
(a)pyrene3-monooxygenase activity, whichwasreduced
almosttozerowhenratswerefed apurifieddiet(5,48).
Inthesestudiespotentinducersofpulmonarybenzo(a)-
pyrene 3-monooxygenase activity were found both in
members of the Brassicae family (e.g., brussel sprouts,
cabbage, and cauliflower) and in naturally occurring
compoundssuchasflavoneandtangeritin. Also, certain
pollutants such as ozone, carbon monoxide, and cad-
mium, butnotNO2decreasepulmonarybenzo(a)pyrene
3-monooxygenaseactivity(49). Thus, numerousfactors
present in our environment and diet may modify the
pulmonary metabolism of inhaled carcinogens such as
benzo(a)pyrene and therefore alter their carcinogeni-
city. The complexity oftheproblem isincreasedbythe
largenumberofmetaboliteswithdifferingbiologicalac-
tivities that may be formed from benzo(a)pyrene by
respiratory and other tissues.
Benzo(a)pyrene ismetabolizedtoavarietyofproducts
includingphenols, dihydrodiols, andglutathioneconju-
gates. Studies by Sims and coworkers in the UK and
JerinaandConneyandcoworkersinthe USrecognized
thatthe ultimate carcinogens frompolycyclic aromatic
hydrocarbons were the bay region diol-epoxides form-
edfromdihydrodiols(50,51). Thegeneralschemeforthe
metabolicactivationofpolycyclicaromatichydrocarbons
is shown in Figure 2 and illustrated specifically with
benzo(a)pyrene inFigure3. AllthemetabolitesinFigure
3 are formed by respiratory tract tissues (44). These
figuresdemonstratethelargenumberofmetabolitesthat
may be formed within the respiratory tract. The poly-
cyclic aromatic hydrocarbon is first metabolized to an
epoxidebythepulmonarymicrosomalornuclearmixed-
function oxidase enzymes (Fig. 2). The epoxides then
either: a)rearrange spontaneously to form thephenol;
b)reactwithglutathionetoform aglutathioneconjugate
eitherspontaneously orinareactioncatalyzedbygluta-
thioneS-transferase: c)arehydratedtoformadihydrod-
iol in a reaction catalyzed by microsomal or cytosolic
epoxide hydrolase; or d) react with cellular macro-
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FIGURE 2. General scheme for the metabolic activation of polycyclic aromatic hydrocarbons illustrating the complexity of metabolism,
the diversity of enzymes involved, and their different subcellular localizations.
Benzo(a)pyrene
g> Watersoluble
glucurmnide
7,8-Dihydrodiol
hydrogen
Metabolic fate ?
Glutathione | <
conjugate
Covalent 7,8,9,10-Tetrahydiotetrol
binding to exocyclic
-NH2 group of
deoayguanosine in DNA
Covalent
binding
Glutathione
conjugate
Tumour Initiation(?)
FIGURE 3. Metabolism of benzo(a)pyrene by tissues from the respiratory tract illustrating the wide array of metabolites of differing
biological activities that may be formed by the drug-metabolizing enzymes in the respiratory tract.
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molecules(Fig. 2)(52). Initially, thefirstthree reactions
werethoughttobedetoxicationreactionswhilethelast
was considered to be the toxic reaction (52). However,
more recent evidence shows that dihydrodiols may be
further metabolized to diol-epoxides, e.g., 7,8-dihydro-
7,8-dihydroxybenzo(a)pyrene (7,8-dihydrodiol) is metab-
olized to 7,8-dihydro-7,8-dihydroxybenzo(a)-pyrene-
9,10-oxide (Fig. 3); it is this diol-epoxide that is bound
toDNAwhenintactcells ortissues areexposed tobenzo-
(a)pyrene (50). These diol-epoxides, but not the parent
dihydrodiols, donotrequire metabolicactivationinorder
to be potent mutagens.
With ratlunghomogenatesand microsomes, benzo(a)-
pyrene was metabolized to 4,5-dihydro-4,5-dihydroxy-
benzo(a)pyrene (4,5-dihydrodiol), 7,8-dihydrodiol, and
9,10-dihydro-9 ,10-dihydroxybenzo(a)pyrene-(9,10-
dihydrodiol)(Fig. 3), as well as3-hydroxybenzo(a)pyrene
(53). Similar metabolites were obtained from benzo(a)-
pyrene using isolated perfused rat lung (10). Cigarette
smoke exposure caused significant increases in 9,10-,
7,8-, and 4,5-dihydrodiols, in 3-hydroxybenzo(a)pyrene,
and in the amount ofcovalently bound radioactivity in
isolated perfused lungsandintratracheallyadministered
[3H]-benzo(a)pyrene (54).
Grover (55) demonstrated the formation ofbenzo(a)-
pyrene 4,5-oxide andthe presence ofepoxidehydrolase
and glutathione S-epoxide transferase using rat lung
microsomes from animals pretreated with the microso-
mal enzyme inducer3-methylcholanthrene. Ofinterest
was the finding that the epoxide hydrolase activity of
lung wasmuchlowerthan thatofliver, whilethe trans-
ferase activity in the lung was higher. While such dif-
ferences in enzymic activities may, in part, determine
the susceptibility of tissues to tumor induction, many
other factors such as DNA repair are also important.
The majority of lung cancers in man arise from a
squamous metaplastic differentiation of the bronchial
epithelium. In the animal model, which gives a similar
histologicalpicturetothatobtainedin man, manyofthe
tumors arise in the trachea. Thus, several studies have
also been carried out on the metabolism of benzo(a)-
pyrene and related polycyclics by short-term organ cul-
turesoftrachea(56,57). Ofinterest wasthe observation
thatthemajormetabolites obtainedfromeitherhuman
bronchial epithelium orrat orhamstertrachea were di-
hydrodiols(10,57). The formation oftheproximate car-
cinogens in the area of the respiratory tract most
susceptible totumorformation maybeofparticularsig-
nificance.
We have also shown striking differences between
routesofcornugation ofbenzo(a)pyreneand 1-naphthol,
a model phenolic substrate, by short-term explant
cultures of peripheral lung from rats and humans (58).
Inrattissuethemajorroute ofconjugation wasglucuro-
nidation, while sulfation was the predominant route
with normal human tissue. Sulfation was amajor route
ofconjugation duringthemetabolism ofbenzo(a)pyrene
by cultured humanbronchus; in the rodent and bovine
species, sulfationandglucuronicacidcornugation ofben-
zo(a)pyrene metabolites were approximately equal. In
thehumantissues, such astrachea, mainstembronchus,
or lowerbronchi, sulfation occurred to a much greater
extentthanglucuronidation. Significant amountsofglu-
tathioneconjugateswere also observed inthedifferent
species (55). In this study, a higher ratio of organic
solvent-extractable metabolitesto water-soluble metab-
olitesofbenzo(a)pyrene wasobservedinspeciesknown
to be susceptible to benzo(a)pyrene-induced carcino-
genesis. This ratio suggested that possible deficiencies
intheconjugatingenzymesmay be animportantfactor
in determining species susceptibility.
Humanbronchialmucosawasable to activate benzo-
(a)pyrene, 7,12-dimethylbenz(a)anthracene, 3-methyl-
cholanthrene, and dibenz(a,h)anthracene intometabo-
litesthat covalentlybound to DNA. In astudy of37 pa-
tients, a 75-fold interindividual variation was found in
thebindingofbenzo(a)pyrene to culturedhumanbron-
chus(59). Followingthecultureofhumanbronchuswith
benzo(a)pyrene, the product bound to DNA was indis-
tinguishable from that formed when the diol-epoxide
7,8-dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide
reacted with DNA. From these studies, it is clear that
the area of the respiratory tract most susceptible to
developlungcancer(i.e., bronchialepithelium)iscapable
ofmetabolicallyactivatingbenzo(a)pyrene toametabo-
lite that covalently binds to DNA. The rates of forma-
tion and removal of reactive metabolites in these cells
may well be critical factors in determining individual
susceptibilities to lung cancer.
Most of the data discussed above implicate the cyto-
chromeP-450-dependentmixed-functionoxidasesystem
in the pulmonary metabolism of benzo(a)pyrene and
other polycyclic aromatic hydrocarbons. Some recent
evidence suggestsapossibleinvolvement ofcooxygena-
tionofpolycyclic aromatichydrocarbons duringthe ox-
idation of polyunsaturated fatty acids (60). Benzo(a)-
pyreneandits7,8-dihydrodiolarecooxidizedtoquinones
and to tetrols, respectively, following incubation with
lungmicrosomesandarachidonic acid (61). Thus, apossi-
bleroleforprostaglandinendoperoxidesynthetaseinthe
metabolic activation of carcinogens and other xeno-
biotics in the lunghas been implicated but not proven.
Thus, in summary, the metabolism ofbenzo(a)pyrene
by different portions of the respiratory tract has been
described. Humanbronchus, aprimetargetfortheaction
ofpolycyclicaromatichydrocarbonsandforthe develop-
mentoflungcancerinman, metabolizesbenzo(a)pyrene
intovariousmetabolites, inparticular, theproximatecar-
cinogen 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene,
whichmay thenbe furthermetabolized to the reactive
diol-epoxide 7,8-dihydro-7,8-dihydroxybenzo(a)pyrene
9,10-oxide that can bind to DNA of the bronchus and
possibly initiate tumor formation.
A large variety of environmental factors such as air
pollution, diet, drugs, andcigarettesmokingbymodify-
ing the pulmonary metabolism ofbenzo(a)pyrene may
either increase or decrease its carcinogenicity. This
alteration in pulmonary enzyme activities by environ-
mentalfactorswillresultininterindividualdifferences
inpulmonarymetabolismandinresponsestopulnonary
toxins.
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4-lpomeanol
It is apparent from the work of Boyd (1) that 4-
ipomeanol, (1-(3-furyl)-4 hydroxypentanone), a furan
found on moldy sweet potatoes, produces a striking
pulmonary toxicity in a number of species. The
characteristic pulmonary toxicity observed is necrosis
of the nonciliated bronchiolar epithelial or Clara cells
(1,38).Followmginivivoadministrationof[14C]ipomeanol
to rats, significantly more covalently bound radioactiv-
ity was observed in lungs than any other tissues. Auto-
radiography revealed that the covalently bound radio-
activitywaspredominantly associated withClaracells,
and in vitro studies suggested that a cytochrome
P-450-dependent monooxygenase was required to ac-
tivate4-ipomeanoltoareactivemetabolite(s)thatbound
covalently tomacromolecules. Whilemuch oftheearly
data suggested that the reactive metabolite of 4-
ipomeanol was the furan epoxide, studies with 2- and
3-methylfuran identified the unsaturated aldehydes
acetylacroleinandmethylbutenedial, respectively, asthe
principalreactive metabolites(62). Thus, intheabsence
offurtherdatawecannotyetconcludethenatureofthe
reactive metabolites of 4-ipomeanol.
Both rat lung and liver were capable of activating
4-ipomeanol to a binding species. However, when the
results were expressed onthe basis ofcovalentbinding
per molecule of cytochrome P-450, the lung appeared
approximately8-foldmoreactivethantheliver. Boyd(38)
andSerabjit-Singh(39)haveindependently shownthat
at least one type of cytochrome P-450 is specifically
localized in the Clara cells. These observations demon-
strate the importance of the qualitative nature of the
cytochrome P-450anditstissuedistributionindetermin-
ing which cells in a specific organ may be predisposed
totoxicity. Thepulmonarytoxicityof4-ipomeanol isap-
parentlymediatedbyreactivemetabolitesgeneratedin
specificcellsinthelung - thatis, themechanismshown
in Figure 1. Recent work with isolated rabbit lung cells
showedthatisolatedClaracellsactivated[14C]ipomeanol
tocovalently bound species at a muchhigherrate than
isolated alveolar Type II cells (63).
Furthersupportforthekeyroleofpulmonarymetabo-
lism of 4-ipomeanol in determining its pulmonary tox-
icitycamefromaseriesofstudieswithenzymeinducers
and inhibitors. Three inhibitors (pyrazole, piperonyl
butoxide, andcobaltouschloride)decreasedbothhepatic
andpulmonarybindingof4-ipomeanolbothinvitroand
invivo, correlating wellwiththe decreased pulmonary
toxicityinvivo(1). Pretreatmentofratswiththeinduc-
ing agents phenobarbitone and 3-methylcholanthrene
caused amarked increase inthe invitrocovalentbind-
ingof4-ipomeanoltoliver, butnottolung microsomes.
These alterations were accompanied by decreased
covalentbindingtolunginvivoanddecreasedpulmon-
ary toxicity. Treatment with 3-methylcholanthrene,
however, causedanincreaseininvivocovalentbinding
in the liver that correlated with centrilobular hepatic
necrosis. Thus, differentialalterationsinthebalance of
theenzymesinthelungandlivercausedbythe3-methyl-
cholanthrene caused ashiftintargetorgantoxicity. The
observation that pretreatment with 3-methyl-
cholanthrene increased both the toxicity and the
covalent binding of 4-ipomeanol in the liver, but de-
creasedtheseactionsinthelung, supportsthehypothesis
that reactive metabolites of 4-ipomeanol will bind in
those cells and tissues in which they are generated
that is, the mechanism in Figure 1.
IthankM. Flaggfortypingthemanuscript andD. Kingforpreparing
the figures.
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